Charu Aggarwal
Penn Medicine · University of Pennsylvania · Perelman Center for Advanced Medicine
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Charu Aggarwal as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:32 UTC. Open this list on ClinicalTrials.gov
- N/ANCT05853887 · Liquid Biopsy Based NGS in Newly Diagnosed NSCLCCharu Aggarwal · active not recruiting · Non Small Cell Lung Cancer Metastatic, Newly Diagnosed NSCLC, Non-Squamous Non-Small Cell Neoplasm of Lung · principal investigator
- N/ANCT05790460 · Telehealth Based Synchronous Navigation to Improve Molecularly-Informed Care for Patients With Lung CancerAbramson Cancer Center at Penn Medicine · terminated · Non-small Cell Lung Cancer · principal investigator
- Ph3NCT05687266 · Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic AlterationsAstraZeneca · active not recruiting · NSCLC · study chair
- Ph1NCT05647122 · First in Human Study of AZD9592 in Solid TumorsAstraZeneca · active not recruiting · Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms · principal investigator
- Ph2NCT04735068 · Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung CancerAbramson Cancer Center at Penn Medicine · completed · Non-Small Cell Lung Cancer, KRAS Mutation-Related Tumors · principal investigator
- N/ANCT03047616 · A Pilot Study to Develop Predictive Biomarkers for the Response to Immunotherapy in Lung CancerAbramson Cancer Center at Penn Medicine · completed · Lung Cancer · principal investigator
- Ph1NCT01997190 · Intrapleural AdV-tk Therapy in Patients With Malignant Pleural EffusionCandel Therapeutics, Inc. · completed · Malignant Pleural Effusion, Lung Cancer, Mesothelioma · principal investigator
- Ph2NCT01773109 · Etirinotecan Pegol (NKTR-102) in NSCLCAbramson Cancer Center at Penn Medicine · completed · Metastatic Non Small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:32 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Pragmatic TrialP50CA271338 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Katharine A. Rendle · fiscal years 2022 to 2026Named on NCT05790460
Most cited trial papers
Clinical-trial papers with this author name in non-small cell lung cancer, ranked by citations from NIH iCite, fetched 2026-11-12 10:32 UTC. The ranking covers the 200 most relevant of 21 PubMed records, and a shared surname and initials can bring in a namesake. All 21 on PubMed
- Pembrolizumab for the treatment of non-small-cell lung cancer.N Engl J Med · 20155,273 citationsRCR 161.1
- Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.J Clin Oncol · 2019989 citationsRCR 35.4
- 281 citationsRCR 16.7
- Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study.Lancet Respir Med · 2019152 citationsRCR 5.0
- Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial.J Immunother Cancer · 2022138 citationsRCR 7.9
- 114 citationsRCR 4.4
- 79 citationsRCR 2.2
- SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).J Thorac Oncol · 201973 citationsRCR 2.3
- 46 citationsRCR 2.9
- Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy.Clin Lung Cancer · 202136 citationsRCR 1.7